ASSESSMENT OF RADIOTHERAPY IN HUMAN NEOPLASMS

选择一种或多种治疗方式(例如，放射 治疗、化疗和手术)都是从经验中衍生出来的 基于对以前治疗过的患者进行的这些药物的试验。 然而，在个别情况下，人们无法预测是否 那个肿瘤会对治疗有反应，也不会有反应的程度 回应。因此，个别患者可能会受到 到一个漫长的疗程，最终可能是 无效的或可能被拒绝的潜在有用的疗法，因为 肿瘤不会有反应的统计可能性。它 希望有一个非侵入性的体内系统来预测 个体是否会对治疗有反应，因此， 优化疗程。 利用新实现的(1)体内磁共振 在1.4T全身成像仪上进行光谱(MRS)检查，我们打算 表征磷代谢产物的变化和 放射治疗对人体肿瘤细胞内pH的影响 并将MRS结果与临床终点相关联。在……里面 为了获得这些研究的统计意义，大量的 患有两种鳞状细胞癌的患者人数 或淋巴瘤(霍奇金或非霍奇金将参与其中 项目。MRS数据将进一步与 黄瓜非整倍体和整倍体种群的分布 用流式细胞仪测定DNA含量。核磁共振 还将进行测量以确定边界， 肿瘤的不均匀和中心性坏死。组织病理学 还将对每个案例进行分析。人们希望， 人类的某些生化过程和放射生物学 肿瘤对分割伽玛射线的反应 还将描绘养生方案。最终，这将是可能的 为了预测治疗是否会控制肿瘤，根据 MRS谱的特征变化，人们可能会 合理选择主要医疗方式，并确定是否需要 一种或多种辅助治疗(如手术、化疗等)

The selection of one or more treatment modalities (e.g., radiation therapy, chemotherapy and surgery) has been empirically derived based on trials with these agents in previously treated patients. However, in the individual case one cannot predict whether or not that tumor will respond to treatment nor the extent of that response. As a consequence, individual patients may be subjected to a protracted course of therapy which ultimately may be ineffective or may be denied a potentially useful therapy because of the statistical likelihood that the tumor will not respond. It would be desirable to have a noninvasive in vivo system to predict whether an individual will respond to treatments and, therefore, optimize the course of therapy. Utilizing the newly implemented (1) in vivo magnetic resonance spectroscopy (MRS) on a 1.4T wholebody imager, we intend to characterize the alterations of phosphorous metabolites and intracellular pH of human neoplasms in response to radiotherapy and correlate the MRS findings with the clinical end points. In order to obtain a statistical significance of these studies, a large number of patient population with either squamous cell carcinoma or lymphoma (Hodgkin or nonHodgkin will participate in this project. The MRS data will be further correlated to the distribution of aneuploid and euploid populations obtained from the measurement of DNA content by flow cytometry. The MRI measurements will also be made to identify the boundary, inhomogeneity and central necrosis of tumors. Histopathological analysis will also be performed for each case. It is hoped that some of the biochemical processes and radiobiology of human neoplasms in response to the fractionated gammairradiation regimen will also be delineated. Ultimately it would be possible to predict whether the treatments will control the tumor base on the characteristic changes in the MRS spectra, and one may more rationally choose the primary modality and decide the need for one or more adjuvant therapies (e.g., surgery, chemotherapy, etc.)